Canada vaccine Coronavirus covid canada Canada

Canada’s Medicago begins late-stage study of COVID-19 vaccine with GlaxoSmithKline

Reading now: 911
globalnews.ca

Medicago said on Tuesday it had started a late-stage study of its experimental COVID-19 vaccine combined with a booster from GlaxoSmithKline.The study plans to eventually enroll 30,000 participants and initially focus on healthy adults, followed by adults over the age of 65 and those with co-morbidities.

Drugmakers partner to develop COVID-19 vaccines aimed at new variants Medicago, which has Canada’s most advanced COVID-19 vaccine project under development, expects to report results from a mid-stage trial of the vaccine in April.The Medicago vaccine uses a technology known as virus-like particles, which mimics the structure of the coronavirus, but contain no genetic material from it.It can be stored at normal fridge temperatures, of 2 C.

Read more on globalnews.ca
The website covid-19.rehab is an aggregator of news from open sources. The source is indicated at the beginning and at the end of the announcement. You can send a complaint on the news if you find it unreliable.

Related News

DMCA